Public Funding for GS1 UK Limited

Medical devices impact every aspect of the public's interaction with the NHS, for prevention, screening, diagnosis, monitoring, and treating of diseases. The safety and effectiveness of these devices is critical to the quality of health outcomes. Traditionally, the great majority of medical device testing is done before they are used on patients ("pre-market"). Manufacturers are required to monitor their devices in clinical use ("post-market"), but in practice this is mainly limited to voluntary reporting and feedback from users. We refer to this ongoing information about medical devices in clinical use as "post-market intelligence." The way we approach this has barely changed in decades. However, recent technological innovations mean that post-market intelligence could be transformed. These innovations include: sophisticated medical device software, connected devices, innovative sensors, and growing hospital medical device databases---which are often managed by trained healthcare scientist staff. We believe that new opportunities can be created by connecting these new and enhanced sources of data about device safety and performance. There is an opportunity for post-market-intelligence to provide much earlier warnings about devices that are not operating as they should, are difficult to use, unreliable, or seem to function poorly in sub-groups of patients. This data could be used by hospitals to better manage their services to patients and have greater confidence in deploying innovative devices in their services. Manufacturers could use data to rapidly detect and address any identified issues with their devices (so called "field action"). Regulators could provide pathways that enable innovative devices to get to patients more quickly, by changing the balance of pre-market and post-market safety and performance evaluation. Our network of organisations will come together to explore this opportunity including how to incentivise adoption of this enhanced post-market vigilance by manufacturers and the NHS. Our network includes medical device manufacturers, companies and universities that specialise in developing standards and tools to connect organisations. It also includes NHS staff who might manage the data that we believe can unlock improvements to the way medical devices are developed, delivered and managed. Our network will also identify how to engage with patients to ensure their voices are heard, especially around how to ensure privacy of their data and trust in the technology and systems we plan to develop.

ERTOC will enable freight users and operators to make more informed choices based on the efficiency and increased awareness of the true financial and environmental cost of transporting goods. This will be realised through the development of a standards based open architecture data hub integrating the following logistics related functions: 1) Multi-modal consignment tracking 2) Capacity sharing (transport sharing) 3) Multi-modal optimisation (transport mode selection) Data from each of these functions (each with their own specific requirements) will be provided via a platform independent, open application programme interface (API). Data fusion and analysis will provide a substantial opportunity for partners to demonstrate the power of the ERTOC concept through the above applications that enable customers to improve the efficiency of their business. A specific benefit of this type of system will be shown through the development of application functions that calculate the actual carbon shipping cost of consignments, providing opportunities for carbon tracking over a number of transport modes. The project will use analysis and classification techniques developed on the innovITS facITS project to assess the data security of the system to inform the architectural design. A thorough security assessment of the system (and the facITS classification/analysis process) will be undertaken and this will lead to suggested modifications of the system and process

Awaiting Public Summary